To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?

By F. Danhier. Journal of Controlled Release, 2016

1,080 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/d66faf748fe55db332d77f189593469d8624e044

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. Wahid Khan
2. Jun Wu
3. S. Hua
4. G. Storm
5. Sindhu Doppalapudi
6. Nagavendra Kommineni
7. Upendra Bulbake

In Biomedical Engineering

1. Fabian Kiessling
2. Jun Wu
3. G. Storm
4. T. Lammers

In Molecular Biology

1. C. Roma-Rodrigues
2. Alexandra R. Fernandes
3. Wahid Khan
4. Fabian Kiessling
5. R. Mendes
6. Jun Wu
7. Pedro Viana Baptista
8. S. Hua

Citations in the corpus

• Liposomal Formulations in Clinical Use: An Updated Review (2017, background): “, were also in phase I clinical trial investigation [154].”
• The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application (2021, methodology): “Some doubt the usefulness of the EPR effect in clinical practice by using the example of Doxil, a polyethylene glycol (PEG) modified-liposome formulation of doxorubicin, which does not appear to significantly improve the benefits of solid tumor treatment compared with parental free drug doxorubicin ”
• Tumor Targeting via EPR: Strategies to Enhance Patient Responses (2018, background): “[17], claiming that EPR is absent in patients, which is not the case and cannot be generalized [14,18]).”
• Targeting Tumor Microenvironment for Cancer Therapy (2019, background): “Theranostics allows, for instance, the detection of a certain biomarker that triggers the release of a drug, while at the same time providing the means to monitor the disease in real time, due to unique optical properties (use as imaging agents, fluorophores or MR contrast agents) [170,172].”
• Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, background): “In addition to the enhanced leakiness of tumorous and inflamed blood vessels, the EPR effect also relates to the observation that solid tumors tend to lack functional lymphatic drainage, which limits the removal of extravasated NNMs from the target site (Maeda et al., 2013; Danhier, 2016).”